Enterprise Value
0.00
Cash
123.6M
Avg Qtr Burn
N/A
Short % of Float
12.15%
Insider Ownership
0.66%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IZERVAY™ (avacincaptad pegol intravitreal solution) Details Age-related macular degeneration, Eye disease , Geographic atrophy | Approved Quarterly sales | |
Zimura (avacincaptad pegol) Details Macular degeneration, Autoimmune disease, Inflammatory disease | Phase 2b Update |